Seeing further.


We’re advancing our RNA-based treatments so patients with cancers and rare diseases can enjoy the moments that matter.

Learn More

Transforming Immunity. Restoring Hope.

We’re committed to redefining the treatment of certain cancers and rare diseases.

Learn More

Scientists. Believers. People.

At Idera, we’re working hard to translate our nucleic acid science into life-changing medicines.

Discover Idera

The Latest

Keep up with what’s happening at Idera Pharmaceuticals.


Idera Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update

EXTON, Pa. , May 09, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”)… Read more 

Idera Pharmaceuticals Announces Acceptance of Several Abstracts related to the ILLUMINATE Tilsotolimod Clinical Development Program at the American Society of Clinical Oncology (ASCO) Meeting

- ILLUMINATE 204 Data selected as subject of a poster discussion session to be held on Monday,… Read more 

Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkpoint Inhibitors at the American Association for Cancer Research (AACR) 2018 Annual Meeting

Triple combination of tilsotolimod (IMO-2125), epacadostat (IDO-1) and anti-PD-1 antibody… Read more 

Learn More


Idera Pharmaceuticals, Inc. Events

Idera Pharmaceuticals, Inc. Events… Read more 

Learn More